Home Latest Articles
Latest Articles
  • Ping HUANG, Quanmin LIU, Yingxuan YU, Lan WANG, Yifang DENG
    World Clinical Drug. 2026, 47(6): 690-696.

    As the largest organ of the human body, the skin serves as the first physical and immune barrier against pathogen invasion, playing a crucial role in safeguarding human health. Currently, in skin research, traditional models such as animal models and two-dimensional cell models have limitations in simulating the complex structure and physiological functions of human skin, thus exhibiting significant deficiencies in the mechanism research of skin diseases and drug development. Skin organoids, as an emerging three-dimensional in vitro model, can highly recapitulate multiple cell types, layered structures, and key functions of human skin, providing a novel tool for skin research. This review summarized the construction technologies of skin organoids and their applications in disease model establishment, regenerative medicine, and wound repair, aiming to offer references for the future applications of skin organoids.

  • Ji CHA, Xueqing GUI, Ziyi CAO, Dingkun GUI, Jingping LI
    World Clinical Drug. 2026, 47(6): 697-703.

    Diabetic osteoporosis(DOP) is a prevalent chronic complication of diabetes mellitus that considerably compromises patients' quality of life. In the management of DOP, Western medicine predominantly relies on hypoglycemic agents, anti-osteoporotic drugs, and lifestyle modifications. Traditional Chinese Medicine(TCM), in contrast, follows the therapeutic principles of nourishing the liver and kidney, strengthening the spleen and Qi, promoting blood circulation, and resolving blood stasis, with a primary emphasis on reinforcing vital energy(strengthening healthy Qi), supplemented by syndrome differentiation and individualized treatment based on specific clinical manifestations. The integrated application of Western and TCM therapies can harness their complementary strengths, thereby enhancing overall therapeutic efficacy. This paper systematically reviews recent advances in the treatment of DOP using Western medicine, TCM, and their combination, aiming to provide a valuable reference for clinical practice.

  • Zhongyin ZHANG, Tingting HU, Mengran GUO, Chenji HU, Linshan JIANG
    World Clinical Drug. 2026, 47(6): 704-708.

    Sicca syndrome is a systemic autoimmune disease characterized by the involvement of exocrine glands. Its main symptoms include dry eyes and dry mouth. Iramud is a small molecule antirheumatic drug with multi-target anti-inflammatory and immunomodulatory effects. This article briefly introduces the disease characteristics and current treatment overview of sicca syndrome, and focuses on reviewing the mechanism of action, clinical efficacy and safety research progress of ilarimod in this disease, as well as its future application prospects.

  • Yongli LIANG, Dan WU, Lixin ZHANG, Huaile ZHONG, Guleng Siri
    World Clinical Drug. 2026, 47(5): 455-461.

    Immunoglobulin A nephropathy(IgAN) is the primary glomerular disease that leads to end-stage renal disease(ESRD), 40% of IgAN patients have progressed to ESRD within 20 years after diagnosis, and it is a common cause of renal failure among young people in China. The current supportive treatment, corticosteroids, and non-specific immunosuppressants have limited effects. New therapies targeting the specific mechanisms of IgAN are urgently needed.This article reviewed the latest progress of hot drugs for IgAN immunotherapy, including B-cell-targeting drugs and complement-targeting drugs, focusing on related pharmacology, clinical research and safety, in order to provide references for research and application.

  • Yongli LIANG, Lutong REN, Lixin ZHANG, Xiaojuan ZHANG, Guleng Siri
    World Clinical Drug. 2026, 47(5): 462-467.

    Immunoglobulin A nephropathy(IgAN) is the most prevalent primary glomerular disease worldwide.Traditional treatments have shown poor efficacy and are associated with numerous adverse reactions. Currently, the continuous emergence of non-immunosuppressive therapeutic drugs has broken the limitations of traditional single-mechanism approaches through multi-target intervention. This article systematically reviewed the pharmacological mechanisms, key clinical evidence, and clinical applications of three hot-spot non-immunosppressive therapeutic drugs such as endothelin receptor antagonists, sodium-dependent glucose transporters 2 inhibitors, and non-steroidal glucocorticoid receptor antagonists, in order to provide a reference for the clinical application.

  • Haifeng HE, Peng XIONG, Dengkun WANG, Changmei NING, Hao ZHOU, Jiao YU
    World Clinical Drug. 2026, 47(5): 468-478.
    Objective

    To investigate the protective effect of Chaishao Liujunzi decoction on the gastric mucosal barrier in mice with liver-stomach disharmony type gastric ulcer(GU), as well as its influence on oxidative stress injury and the Kelch-like ECH-associated protein (Keap)1/nuclear factor erythroid 2-related factor(Nrf2)/heme oxygenase(HO)-1 signaling pathway.

    Methods

    Forty Kunming mice, half male and half female, were randomly divided into the blank control group, model group, omeprazole group, and Chaishao Liujunzi Decoction group, with 10 mice in each group. The liver-stomach disharmony type GU model was established by using the "emotional stimulation intervention method+intragastric administration of anhydrous ethanol method". After successful establishment of the model, the corresponding drugs were administered by gavage for 2 weeks. Hematoxylin-eosin staining was used to observe the pathological changes of the gastric mucosa. AB-PAS staining was employed to examine the distribution of mucopolysaccharides in the gastric mucosa. Scanning electron microscopy was used to observe the ultrastructural morphology of the gastric mucosa. The DHE fluorescence probe method was used to detect the level of reactive oxygen species(ROS), malondialdehyde(MDA),glutathione peroxidase(GSH-Px), superoxide dismutase(SOD), interleukin(IL)-6, tumor necrosis factor(TNF)-α in the gastric tissue. Immunofluorescence was performed to observe the positive expression of mucin(MUC)5AC and cyclooxygenase(COX)-2 proteins in the gastric mucosa. Immunoblotting was conducted to detect the relative expression of Keap1, Nrf2, HO-1, occludin, epithelial cadherin(E-cadherin), and MUC1 proteins in the gastric tissue.

    Results

    Compared with the model group, both the omeprazole group and the Chaishao Liujunzi decoction group showed reduced pathological damage of gastric mucosa, increased mucopolysaccharide content, and alleviated ultrastructural damage. The levels of ROS, MDA, IL-6, and TNF-α decreased(P<0.01), the levels of SOD and GSH-Px increased(P<0.01), the average fluorescence intensity of MUC5AC and the relative expression levels of Nrf2, HO-1, and occludin proteins increased(P<0.01), and the average fluorescence intensity of COX-2 and the relative expression level of Keap1 decreased(P<0.01). Compared with the omeprazole group, the Chaishao Liujunzi Decoction group exhibited lower levels of SOD and GSH-Px and the expression level of Keap1(P<0.01), while the expression levels of Nrf2, HO-1, occludin,E-cadherin, MUC1 proteins and the average fluorescence intensity of MUC5AC increased(P<0.05).

    Conclusion

    Chaishao Liujunzi decoction can alleviate gastric mucosal pathology and ultrastructural damage, reduce ROS production and lipid peroxidation, enhance the activity of antioxidant enzymes, down-regulate the levels of inflammatory factors, and up-regulate the protein expressions of occludin, E-cadherin, MUC1 and MUC5AC to increase mucopolysaccharide content in liver-stomach disharmony type GU mice to protect gastric mucosal barrier. Its protective mechanism may be related to regulating the Keap1/Nrf2/HO-1 signaling pathway, thereby mediating antioxidant, anti-inflammatory and mucosal barrier repair. Moreover, Chaishao Liujunzi decoction is superior to omeprazole in some indicators.

  • Xuerong YANG, Juanfei XU, Hao LU, Lili WANG, Lewei TAO
    World Clinical Drug. 2026, 47(5): 479-485.
    Objective

    To explore the clinical efficacy of DM120 decoction as an adjuvant treatment for diabetic nephropathy(DN) and its effects on transforming growth factor(TGF)-β1 and interleukin(IL)-6.

    Methods

    A total of 80 patients with DN admitted to the Endocrinology Department of our hospital were enrolled, and divided into the control group(standard treatment) and the treatment group(standard treatment+DM120 decoction) by simple random sorting method, with 40 cases in each group. The changes in renal function, urine protein, micro-inflammatory factors, and the traditional Chinese medicine(TCM) syndrome scores of Qi-yin deficiency combined with blood stasis syndrome before and after treatment were analyzed and compared between the two groups.

    Results

    After treatment, the serum creatinine in the treatment group decreased compared with that before treatment(P<0.05), the glomerular filtration rate increased(P<0.05), and the urine protein indicators in both groups decreased compared with those before treatment(P<0.05). The improvement of these indicators in the treatment group was better than that in the control group at the same time point(P<0.05). The levels of serum and urine TGF-β1 and IL-6 in both groups decreased compared with those before treatment(P<0.05), with a greater reduction observed in the treatment group than in the control group(P<0.05). The efficacy scores of TCM syndromes such as dry throat, dry mouth, fatigue, overeating and hunger, shortness of breath, laziness of speech, five-centers restlessness, lower extremity edema, and limb pricking pain in the treatment group were higher than those in the control group(P<0.05).

    Conclusion

    DM120 decoction as an adjuvant treatment for DN has definite efficacy.It can relieve symptoms, protect renal function, reduce urine protein and blood urine TGF-β1 and IL-6 levels, improve micro-inflammatory state, and is worthy of promotion and application.

  • Yinghui JIANG, Wenying SHANG, Xiaojuan ZHANG, Shilei ZHANG, Weiwei LU, Zheng LI
    World Clinical Drug. 2026, 47(5): 486-494.
    Objective

    To explore the therapeutic effect of fenofibrate combined with dapagliflozin in the treatment of diabetic nephropathy(DN).

    Methods

    This study was a prospective randomized controlled trial. 500 patients with DN who admitted to the department of nephrology, Hebei hepatopathy hospital of traditional Chinese medicine from January 2021 to January 2024 were selected and randomly divided into the control group and the observation group, with 250 cases in each group. The control group was treated with dapagliflozin orally, while the observation group was treated with fenofibrate in addition to the treatment of the control group. Both groups were treated continuously for 12 months. The primary endpoint was the renal composite hard endpoint[defined as a declinein estimated glomerular filtration rate(eGFR)of ≥40% or progression to end-stage renal disease] at 12 months of treatment, and the secondary endpoints included differences in blood glucose indicators, renal function indicators, inflammatory factors, microcirculation indicators,oxidative stress indicators before treatment, at 6 and 12 months of treatment, as well as safety comparisons.

    Results

    After 12 months of follow-up, the incidence of the renal composite hard endpoint in the observation group was lower than that in the control group(P<0.05). At 6 and 12 months, the fasting blood glucose, glycosylated hemoglobin, serum creatinine,24-hour urinary microprotein excretion rate, β2 microglobulin, C-reactive protein, interleukin-6, endothelin-1, fibrinogen,whole blood low shear viscosity, malondialdehyde in the observation group were lower than those in the control group,while the superoxide dismutase and glutathione peroxidase were higher than those in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).

    Conclusion

    Fenofibrate combined with dapagliflozin can significantly reduce the risk of the renal composite hard endpoint in patients with DN, demonstrating a clear long-term renal protective effect. It may achieve this through multiple pathways such as synergistically regulating blood glucose, protecting renal function, inhibiting the systemic inflammation, improving microcirculation, and reducing oxidative stress damage. Moreover, it does not increase adverse reactions, with good safety.

  • Yuwei LIU, Wei YANG, Xiaohua GOU, Shining JIAN, Lizhu LUO
    World Clinical Drug. 2026, 47(5): 495-501.
    Objective

    To explore the impact of anlotinib combined with toripalimab on the therapeutic efficacy and safety of patients with advanced non-small cell lung cancer(NSCLC).

    Methods

    A total of 88 patients with advanced NSCLC admitted to our hospital from March 2023 to June 2025 were selected. They were divided into the conventional group(anlotinib) and the combined group(anlotinib+teprotumumab) according to different treatment regimens. The objective response rate(ORR) and disease control rate(DCR) were compared between the two groups. The levels of serum indicators, tumor markers, quality of life and safety were evaluated between the two groups.

    Results

    The ORR and DCR in the combined group(38.30% and 87.24%) were both higher than those of the conventional group(17.07% and 68.29%, P<0.05). Compared to before treatment, the levels of serum indicators and tumor markers in both groups were lower(P<0.05), and the combined groups was obviously lower than the conventional group(P<0.05). The scores of the functional assessment of cancer therapy-lung cancer(FACT-L) scale of the two groups increased compared to before, and the scores of the Patient Health Questionnaire-9(PHQ-9) decreased(P<0.05). Moreover, the FACT-L score of the combined group was higher than that of the conventional group, and the PHQ-9 score was lower than that of the conventional group(P<0.05). There was no significantly difference in the incidence of adverse reactions between the two groups(P>0.05).

    Conclusion

    The combination therapy of anlotinib and toripalimab can significantly reduce the levels of serum tumor markers in patients with advanced NSCLC, improve their quality of life, and has remarkable efficacy.Moreover, it demonstrates good safety.

  • Xiaoqin SHEN, Yongwei LI, Debing ZHOU
    World Clinical Drug. 2026, 47(5): 502-507.
    Objective

    To evaluate the therapeutic mechanism of mepolizumab in type 2 inflammatory bronchial asthma.

    Methods

    The clinical data of 102 patients with type 2 bronchial asthma who were treated in our hospital from March 2024 to January 2025 were collected retrospectively. They were grouped according to different treatment regimens. The control group treated with budesonide formoterol and oral glucocorticosteroid(OCS) prednisone, while the observation group received mepolizumab in addition to the control group. The conditions of both groups after 6 months of treatment were collected and compared, including asthma control test(ACT) score, OCS dosage, eosinophil(EOS) count,immunoglobulin(Ig)E, fractional exhaled nitric oxide(FeNO), forced vital capacity(FVC), forced expiratory volume in one second(FEV1), peak expiratory flow(PEF), total bronchial surface area(TA), lumen area(LA), and wall area of tube(WA), and the number of readmissions due to asthma exacerbation over a 12-month follow-up period.

    Results

    After treatment, the ACT score and OCS dosage in the observation group decreased more significantly compared with the control group(P<0.05), while the EOS count, IgE, and FeNO were lower in the observation group than in the control group(P<0.05), and the FVC, FEV1/FVC, and PEF in the observation group were higher than those in the control group(P<0.05).The LA in the observation group was higher than that in the control group(P<0.05), and the WA was lower than that in the control group(P<0.05), the 12-month follow-up showed that the number of re-admissions due to asthma exacerbation in the observation group was less than those in the control group(P<0.05). The multivariate logistic regression analysis showed that baseline EOS and FeNO were independent predictors for evaluating treatment response based on the ACT scoring(P<0.05).

    Conclusion

    Mepolizumab helps control the condition of type 2 inflammatory bronchial asthma, reduces the dosage of OCS. The main mechanism of action is speculated to be targeting the blockade of type 2 inflammatory biomarkers and improving airway remodeling.

News